NASDAQ$TRVI
Trevi Therapeutics Inc · Q1 2025 earnings
Q1 2025 earnings ·
Briefing
Trevi Therapeutics reported Q1 2025 a net loss of $10.3M, diluted EPS of $(0.08).
For Q1 2025, Trevi Therapeutics reported net loss was $10.3M, diluted EPS was $-0.08. Management discusses operating trends, liquidity, and outlook in the quarterly filing.
- Net loss $10.3M.
- Diluted EPS $-0.08.
- MD&A highlights operating priorities, liquidity, and sector-specific risks.
Headline financials
Revenue & EPS history
Trevi Therapeutics Inc · Revenue · Quarterly
$0
Forward guidance
Life-sciences outlook focuses on clinical milestones, R&D spend, and cash runway.
Tailwinds
- Pipeline readouts and partnership potential.
- Cash resources to fund development.
Headwinds
- Trial and regulatory risk.
- Operating losses until commercialization.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 12 quarterly earnings reports · overlaid with Q1 2025
+0.7%
Avg return
Earnings day
-1.3%
Avg return
5 days after
+8.6%
Avg return
30 days after
42%
5 / 12 earnings
Positive
+8.1%
Q2 2024
Best reaction
-4.5%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.0% | +0.9% | -3.1% | |
| Q4 2025 | -4.5% | -3.8% | +36.1% | |
| Q3 2025 | -3.3% | -4.6% | +7.8% | |
| Q1 2025 | -0.9% | -3.1% | +6.0% | |
| Q3 2024 | +2.6% | +1.7% | -8.6% | |
| Q2 2024 | +8.1% | +4.2% | +13.9% | |
| Q1 2024 | -1.4% | -7.1% | -16.0% | |
| Q3 2023 | +0.0% | -6.0% | -16.1% | |
| Q2 2023 | +4.8% | +3.5% | +0.4% | |
| Q1 2023 | +0.0% | -2.2% | +85.9% | |
| Q3 2022 | +0.0% | +14.0% | +20.7% | |
| Q2 2022 | +0.2% | -13.1% | -23.7% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro